Category Archives: Pharmacogenomics

Drug Half-life | An Overview - Pharm Lect 10
This lecture provides an overview of drug half-life. View other posted videos below: (1) Pharmacokinetics Core concepts: youtu.be ---- DRUG ABSORPTION Videos: (2) Drug Absorption Overview: youtu.be (3) Bioavailability: youtu.be --------- DRUG DISTRIBUTION Videos: (4) Drug Distribution Overview: youtu.be (5) Volume of Distribution: youtu.be ------------------ DRUG METABOLISM Videos: (6) First Pass Metabolism: youtu.be (7) Phase I Metabolism: youtu.be (8) Phase II Metabolism: youtu.be (9) First Order and Zero Order Kinetics: youtu.be (10) Drug Half-life: youtu.be (11) First-order elimination rate constant: youtu.be ------------------------------------------ DRUG ELIMINATION / EXCRETION (12) Drug Clearance: [not yet posted] (13) Practice problems: [not yet posted] (13) Dosage Regimens: [not yet posted] --------------------------------------------------------------------- Factors That Affect Drug Metabolism: (14) Enzyme Induction: youtu.be (15) Competitive Inhibition Overview: youtu.be (16) Competitive Inhibition of Statins: youtu.be (17) Acetaminophen toxicity (Clinical Correlate): [Not yet posted] (18) Pharmacogenomics Overview: youtu.be (19) Slow Acetylators - Pharmacogenomics: [not yet posted]From:Areo SaffarzadehViews:148 4ratingsTime:11:44More inEducation

Originally posted here:
Drug Half-life | An Overview - Pharm Lect 10 - Video

23- Pharmaceutical BiotechnologySG Part IIb. Pharmacogenomics and Personalized Medicine.mov
Encoded in the DNA sequence of our individual genome is the genetic program to build, maintain, and adapt all our tissues and their functions. Each human genome contains 200000 coding elements (exons) and millions of regulatory elements defining complex signaling and regulatory networks. Pharmacogenomics is the study of how an individual #39;s genetic inheritance affects the body #39;s response to drugs. Personalized Medicine offers treatments and diagnostics for the future based on a patients #39; DNA sequence. Sequencing and analysis of the human genome #39;s six billion base pairs is now rapid and affordable. studies on drug metabolism can now be based on individual genomics.From:Albert KauschViews:1 0ratingsTime:01:12:31More inEducation

Here is the original post:
23- Pharmaceutical BiotechnologySG Part IIb. Pharmacogenomics and Personalized Medicine.mov - Video

GIA announces the release of a comprehensive global report on Spectrometers and Spectrophoto/Fluorometers markets. The global market for Spectrometers and Spectrophoto/Fluorometers is projected to reach US$18.4 billion by the year 2018, driven by increasing demand from various industries, and advancements in the fields of drug discovery and development, pharmacogenomics, and metabolomics. Development of advanced instruments and growing popularity and portable instruments bodes well for the future of the market.

San Jose, California (PRWEB) October 19, 2012

As stated by the new market research report on Spectrometers and Spectrophoto/Fluorometers, developed markets such as the United States, Europe and Japan account for a predominant share of the worldwide market. Government stimulus programs have also contributed considerably to the growth in the spectroscopy market. In developed regions, demand would be largely driven by the advent of portable, sturdy and affordable spectrometers, which feature advanced technologies such as spectral bandwidth and operation frequency range. Advanced spectrometers are aimed at addressing the emerging demands of areas such as mineralogy, medicine, environment, pharmaceuticals and biochemistry. Despite the continued dominance of developed regions, emerging economies specifically in Asia-Pacific, such as India and China, and Latin America are expected to offer newer opportunities owing to the different economics as well as application needs.

Molecular Spectroscopy represents the largest product category in the global Spectrometers and Spectrophoto/Fluorometers market. The segment is expected to post modest growth in the coming years driven primarily by the sustained adoption and demand for handheld instruments across various market segments. The US represents the single largest market for molecular spectroscopy. Atomic Spectroscopy, another major segment, is expected to benefit from the growing demand from X-ray and life science industries. The most widely deployed devices within the atomic spectroscopy market include XRF (X-ray fluorescence) and XRD (X-ray diffraction). Mass Spectrometry (MS) represents the fastest growing product segment in the global Spectrometers and Spectrophoto/Fluorometers market. Increasing developments in the areas of medical research, environment and food safety are expected to bolster MS market. Advent of technologically advanced products and the growing need to replace existing or obsolete systems also presence potential opportunities for the MS market.

Global spectrometry market is both concentrated and fragmented because of the diversity of technologies. Major players profiled in the report include AB SCIEX, Agilent Technologies Inc., Bruker Daltonics Inc., Digilab Inc., Extrel CMS LLC, FOSS NIRSystems Inc., Hitachi High-Technologies Corp., JEOL Ltd., Ocean Optics Inc., PerkinElmer Inc., Rigaku Corporation, Shimadzu Corporation, Spectris Plc, Stellar Net Inc., Thermo Fisher Scientific Inc., and Waters Corporation.

The research report titled "Spectrometers and Spectrophoto/Fluorometers: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of trends, issues, strategic industry activities, and profiles of major companies worldwide. The report provides market estimates and projections across geographic markets such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, and Rest of Europe), Asia Pacific, Latin America, and Rest of World. Product segments analyzed include Molecular Spectroscopy (UV-Vis Spectrophotometers, Raman Spectrometers, Nuclear Magnetic Resonance (NMR), Near Infrared (NIR) Spectrometers, FTIR Spectrometers, and Others); Atomic Spectroscopy (Ark/Spark Spectrometers, Plasma Spectrometers (ICP, ICP-MS), Atomic Absorption Spectrometers, and Others); Hyphenated Spectrometry (LC-MS, GC-MS); Mass Spectrometry; Fluorescence Spectrometers; and Accessories.

For more details about this comprehensive market research report, please visit

http://www.strategyr.com/Spectrometers_And_Spectrophoto_Fluorometers_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Originally posted here:
Advanced Products & Expanding Applications to Drive Sales of Spectrometers and Spectrophoto/Fluorometers, According to ...

ScienceDaily (Oct. 15, 2012) Personalized genomic medicine is hailed as a revolution that will empower patients to take control of their own health care, but it could end up taking control away from patients and limiting their treatment choices, concludes an article in the Hastings Center Report. A commentary responding to the article, by the editorial director of Health and Family at Consumer Reports, also appears in the journal.

Genomic science provides two categories of data, the authors write: pharmacogenomic information and genomic susceptibility information. Pharmacogenomic information forecasts how an individual might respond to a particular therapy. Genomic susceptibility testing predicts a patient's chances of warding off or succumbing to an environmental threat or disease.

Genomic medicine's stakeholders -- including direct-to-consumer genetic testing companies, private research centers, and the National Institutes of Health -- are deeply invested in promoting how this information will benefit patients. The authors call this "empowerment rhetoric." And yet the added knowledge that comes from both pharmacogenomic information and genomic susceptibility information could have a negative impact on how much power a patient really has.

The results gleaned from pharmacogenomic information could pressure patients to comply with physicians' recommendations, the authors suggest, because molecular profiling would allow doctors to give orders with more authority. "In fact, because genomic medicine generates more risk information and makes that information the key lens for approaching health and disease, patients may actually find that they have less ability to influence health care decisions and treatments," the authors state.

The virtues of genomic susceptibility information could also go awry. First, because disease prevention relies heavily on lifestyle changes, responsibility is shifted from doctor to patient. Patients who don't make the "right" choices could be deemed irresponsible, the article says. Second, genomic information can for the time being only reveal the health risks of groups of people. Rather than provide individualized assessments, it classifies people into "genetic superfamilies." The authors argue that "population classification schemes based on racial and ethnic categories can be actively disempowering for individuals, by encouraging potentially prejudicial associations between their group affiliations and health care risks."

Patient empowerment is marketed as a paradigm shift because it puts medical data in the hands of the consumer, not just the doctor. But the authors conclude that the focus on empowerment could clash with the reality of what patients are willing or able to do with the information they receive. "The idea of patient empowerment may run up against not only the limits of patients' control over their health, but also the limits of patient control over health care systems," the article says.

The authors are Eric T. Juengst, director of the Center for Bioethics and professor in the Departments of Social Medicine and Genetics at the University of North Carolina, Chapel Hill; Michael A. Flatt, a doctoral candidate in sociology at Case Western Reserve University; and Richard A. Settersten, Jr., professor of social and behavioral health sciences and endowed director of the Hallie E. Ford Center for Healthy Children and Families in the College of Public Health and Human Sciences at Oregon State University.

In a commentary on the article, Ronni Sandroff, editorial director of Health and Family at Consumer Reports, acknowledges that pharmacogenomics could take control away from a patient if a health insurance company opted not to cover a medicine that was shown to work infrequently in people with a particular genetic makeup. But even an increase in patient empowerment can have downsides if it shifts the responsibility for health care to patients and stigmatizes people who do not, or cannot, make the "right" health choices. Sandroff notes that the greatest challenge in preventive medicine is getting people to eat less, exercise more, and reduce stress. Whether or not genetic susceptibility information will actually empower patients by propelling them toward healthier lifestyles is unknown. "This is a question that needs more serious study," she writes.

Still, Sandroff says that consumer participation in genetic health research -- "a new and growing factor" -- could help advance scientific knowledge. "That makes it something that professionals should be wondering how to enhance and encourage, rather than fear," she writes.

Share this story on Facebook, Twitter, and Google:

Originally posted here:
Personalized genomic medicine: How much can it really empower patients?

DR. NAGELE RECOGNIZED FOR FORMATIVE RESEARCH AND CLINICAL WORK

Newswise Washington, D.C. The American Society of Anesthesiologists (ASA) today presented Peter Nagele, M.D., M.Sc. with its 2012 ASA Presidential Scholar Award. Dr. Nagele, well known for his translational research in the area of perioperative pharmacogenomics and myocardial infarction, received the award at the ANESTHESIOLOGY 2012 annual meeting in Washington, D.C.

Dr. Nagele received his medical education at Leopold-Franzens University in Innsbruck, Austria. He then completed his residency in anesthesiology and critical care medicine at the University of Vienna, Austria.

As a resident, Dr. Nagele was an investigator on the first human safety and efficacy study examining xenon as an anesthetic in humans. He then spent two years with C. Michael Crowder, M.D., Ph.D. at Washington University in St. Louis to research how to use genetic techniques to study mechanisms of anesthetic action in the model organism Caenorhabditis elegans (C. elegans).

After his residency, Dr. Nagele returned to Washington University in 2005 to continue his interest in translational research under the advice and guidance of Dr. Crowder and Evan D. Kharasch, M.D, Ph.D., recipient of the 2011 ASA Excellence in Research Award.

In 2008, Dr. Nagele received a FAER mentored research training grant to study the influence of nitrous oxide on postoperative myocardial infarction. The results of this important clinical trial were presented at the ANESTHESIOLOGY 2012 annual meeting.

On behalf of Anesthesiology, we are pleased to present Dr. Nagele with the 2012 ASA Presidential Scholar Award, said James C. Eisenach, M.D., Editor-in-Chief of Anesthesiology. We recognize Dr. Nageles many achievements as a clinical anesthesiologist so early on in his career. We look forward to his many additional contributions to come.

Dr. Nagele currently serves as an Assistant Professor in the Department of Anesthesiology at Washington University. In addition to his major research interests, Dr. Nagele continues to be actively involved in the specialty of trauma anesthesiology and is the head of the departments section on trauma anesthesiology.

The American Society of Anesthesiologists Anesthesiologists: Physicians providing the lifeline of modern medicine. Founded in 1905, the American Society of Anesthesiologists is an educational, research and scientific association with 48,000 members organized to raise and maintain the standards of the medical practice of anesthesiology and improve the care of the patient.

For more information on the field of anesthesiology, visit the American Society of Anesthesiologists website at asahq.org. For patient information, visit LifelinetoModernMedicine.com.

Read more here:
ASA Presents Peter Nagele, M.D., M.SC. with 2012 Presidential Scholar Award

ROCHESTER, N.Y.--(BUSINESS WIRE)--

ACM Global Central Lab, the central laboratory that continually defines the customer-service standard with its flexible approach, has expanded its clinical trials services with the introduction of Drug-Induced Organ Toxicity (DIOT) Monitoring.

The DIOT Monitoring program provides trending reports for any conventional biomarkers tested, which is tailored to client requirements. It focuses primarily on real-time detection and monitoring of elevated liver toxicity biomarkers, which signal potential drug-induced liver injury (DILI). This program rigorously follows the 2009 FDA Guidance for Industry on Drug-Induced Liver Injury. Other organ toxicity monitoring services offered include Drug-Induced Kidney Injury and Drug-Induced Bone Marrow Injury.

Our clients are very interested in better ways to detect DIOT, and particularly DILI, as it is a major cause for the withdrawal of drugs and drug candidates, said Kathleen Murray, executive director, Scientific Affairs at ACM Global Central Laboratory. As part of our DIOT surveillance services, our scientific and data management experts work in close collaboration with our clients to provide the optimal monitoring service for their studies.

The novel DIOT Monitoring service provides clients with real-time trending reports that are generated when the critical level of each analyte is detected in a patient. Once entered in the surveillance system, the patient will continue to be monitored by ACM Global scientists until the end of the study. As part of the DIOT service, and at client request, ACM Global scientific staff will be availablefor consultationto assist in an enhanced assessment of the patients impacted.

To learn more, register for the Oct. 17 webinar on Drug-Induced Organ Toxicity (DIOT): The Early Detection and Management of Elevated Biomarkers to Ensure Patient Safety with ACM Globals Head of R&D Dr. Andrew Botham, Medical Liaison on the Scientific Affairs team Dr. Maria-Magdalena Petru and Chief Commercial Officer Mark Engelhart. Or download the latest Clinical Insight report on Biomarkers of Toxicity Panel in Clinical Trials.

About ACM Global Central Lab

ACM Global Central Lab offers a flexible approach and a focus on precision to optimize the clinical study outcomes for our clients. ACM Global performs 20 million diagnostic tests each year, offering more than 1,500 individual assays, spanning virtually all medical disciplines, including pathology, microbiology, flow cytometry and pharmacogenomics. ACM Globals services extend to more than 60 countries, with all tests conducted and managed from central lab facilities and a seamless data management process providing a single global database.

For more information, visit http://www.acmgloballab.com, our Central Labs in Focus blog or call +1-866-405-0400.

Read the rest here:
ACM Global Central Laboratory Introduces Real-Time Monitoring of Potential Drug-Induced Organ Toxicity